BIODESIX, INC. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
BIODESIX, INC. (BDSX) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $7.53 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-02-26
- BIODESIX, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $7.53M, a 26.16% increase from fiscal 2024.
- BIODESIX, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $5.97M.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month |
|---|---|
| 2025-12-31 | $7.53M 10-K · filed 2026-02-26 |
| 2024-12-31 | $5.97M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |